Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Deep Sequencing

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Deep Sequencing. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-004927-27 Sponsor Protocol Number: RELAIS Start Date*: 2014-12-17
    Sponsor Name:Med. Univ. Wien, Innere Med. I
    Full Title: REgorafenib’s Liquid BiopsY (RELY): A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer. a non-profit investigator-init...
    Medical condition: non-resectable pretreated colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000799-32 Sponsor Protocol Number: PROTEST Start Date*: 2011-06-08
    Sponsor Name:Fundació Lluita contra la SIDA
    Full Title: Use of genotypic HIV-1 tropism testing in proviral DNA to guide CCR5 antagonist treatment in subjects with undetectable HIV-1 viremia
    Medical condition: Human immunodeficiency virus (HIV) infection.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008922 Chronic infection with HIV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-000358-26 Sponsor Protocol Number: BETAF-RED Start Date*: 2022-05-11
    Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer
    Full Title: Safety, tolerability, and efficacy of a dose reduction strategy based on bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-infected adults.
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10008919 Chronic HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004355-33 Sponsor Protocol Number: MH002-UC-201 Start Date*: 2021-09-23
    Sponsor Name:MRM Health NV
    Full Title: Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Mechanistic Effects, and Effects on Disease Activity of MH002 in Subjects with Mild to Moderate Ulcerative Colitis: A First-in...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004557-24 Sponsor Protocol Number: UKM17_0056 Start Date*: 2019-07-29
    Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel
    Full Title: Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2020-001571-32 Sponsor Protocol Number: APHP200406 Start Date*: 2020-04-15
    Sponsor Name:Assistance Publique Hôpitaux de Paris
    Full Title: Low dose of IL-2 In Acute respiratory DistrEss syndrome related to COVID-19 LILIADE-COVID
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005394-31 Sponsor Protocol Number: 12/0219 Start Date*: 2014-04-01
    Sponsor Name:UCL
    Full Title: MS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis
    Medical condition: Mutliple Sclerosis (Secondary Progressive)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004106-34 Sponsor Protocol Number: Dastop2October17th2016 Start Date*: 2017-03-06
    Sponsor Name:Uppsala University Hospital
    Full Title: PERSISTENCE OF MAJOR MOLECULAR REMISSION IN CHRONIC MYELOID LEUKEMIA AFTER a second stop of TKI TREATMENT in patients who failed an initial stop attempt: A prospective multicenter study .
    Medical condition: Chronic Myeloid Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing) DK (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005121-21 Sponsor Protocol Number: THEROS Start Date*: 2018-11-13
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabol...
    Medical condition: Non-small-cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2018-003481-13 Sponsor Protocol Number: NEAT44 Start Date*: 2019-01-15
    Sponsor Name:NEAT ID Foundation
    Full Title: An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease. The Late Presenter ...
    Medical condition: Patients who present late on during their acquisition of the HIV-1 (Human Immunodeficiency Virus)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) DE (Ongoing) ES (Ongoing) BE (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000782-53 Sponsor Protocol Number: UNITO-MM-01/FORTE Start Date*: 2015-01-12
    Sponsor Name:Università degli Studi di Torino-Dipartimento di Biotecnologie Molecolari e Scienze della Salute
    Full Title: A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as pre transplant INDUCTION and post transplant consolidation or CARFILZOMIB, LENALIDO...
    Medical condition: NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003000-39 Sponsor Protocol Number: 2018.0158 Start Date*: 2019-01-09
    Sponsor Name:St George’s University of London
    Full Title: A Multi-centre, Multiple-dose, Open-label Study to Investigate the Safety, Tolerability, Pharmacodynamics, and Efficacy of Erythrocyte Encapsulated Thymidine Phosphorylase (EE-TP) in Patients with ...
    Medical condition: Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10058799 Mitochondrial encephalomyopathy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-005028-40 Sponsor Protocol Number: MOLTO Start Date*: 2019-08-29
    Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA
    Full Title: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL
    Medical condition: Richter syndrome of chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003296-34 Sponsor Protocol Number: OTX116505 Start Date*: 2014-01-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Oteli...
    Medical condition: NOT1DM is an autoimmune disease. This means that the immune system, the part of the body which usually helps to fight infections, mistakenly attacks cells that produce insulin in the body. Insulin ...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10003814 Autoimmune disease, not elsewhere classified LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001102-34 Sponsor Protocol Number: CML1315 Start Date*: 2015-09-15
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Optimizing Ponatinib USe (OPUS). Studio GIMEMA di fase 2 sull¿efficacia e sul profilo di rischio di ponatinib, 30 mg al giorno, in pazienti con Leucemia Mieloide Cronica (LMC) in Fase Cronica, resi...
    Medical condition: Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005531-13 Sponsor Protocol Number: MED3-201401 Start Date*: 2015-11-26
    Sponsor Name:Univerity of Bonn
    Full Title: Multicenter, open-label single arm phase II study testing the tolerability and the efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Imatinib, ...
    Medical condition: Chronic Phase Chronic myelogenous leukaemia( CP-CML) patients who either developed intolerance or treatment failure to previous Imatinib, Dasatinib or Nilotinib as 1st or 2nd line therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002106-68 Sponsor Protocol Number: CTU/2020/354 Start Date*: 2020-07-16
    Sponsor Name:University College London Comprehensive Clinical Trial Unit
    Full Title: Favipiravir, lopinavir/ritonavir or combination therapy: a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
    Medical condition: SARS-CoV-2 (Corona virus) infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-002806-28 Sponsor Protocol Number: SOLTI-1502 Start Date*: 2019-10-25
    Sponsor Name:SOLTI
    Full Title: TARGETING THE PAM50 HER2-ENRICHED PHENOTYPE WITH ENZALUTAMIDE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER
    Medical condition: Male or pre/post-menopausal women age ≥ 18 years with advanced HR+/HER2-negative locally advanced/metastatic breast cancer resistant to endocrine therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004213-41 Sponsor Protocol Number: 5172-048 Start Date*: 2014-05-30
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: A Phase II Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection who failed prior Dire...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10047457 Viral hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001691-41 Sponsor Protocol Number: EMN29 Start Date*: 2021-12-28
    Sponsor Name:European Myeloma Network
    Full Title: A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPL...
    Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:47:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA